Investing in healthcare stocks has gained momentum in Q2 2024 as the S&P 500 Health Care sector outperformed the broader market with a 5.2% monthly gain. Analysts cite increased demand for AI-driven diagnostics and biotech innovation as catalysts, with Pfizer and Moderna both showing higher-than-expected quarterly revenues. Dhar adds that AI can help average investors better understand risk management. AI can quickly compile information about current stock performance and generate data-driven forecasts. To illustrate the short- and long-term economic and societal costs of underinvestment, Deloitte examined three chronic conditions: type 1 diabetes (often developing between ages 10–14 and costing families up to $18,306 annually in some regions), mood and anxiety disorders (affecting about 26 per cent of youth ages 12–17), and epilepsy. Without early intervention and proper health supports, these chronic conditions worsen over time, leading to increased school absenteeism, reduced future employment opportunities, heightened caregiver burden, and escalating costs to families and the health system. Investing in healthcare has enjoyed support from favorable currency movements, as a weaker USD boosted overseas earnings for multinational drug companies. FX tailwinds may persist given current Fed policy cues.
